2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one | 95207-74-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one
• 英文别名: 7-Acetamino-benzosuberon-(1)；N-(5-Oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)acetamide；N-(5-oxo-6,7,8,9-tetrahydrobenzo[7]annulen-2-yl)acetamide
• CAS: 95207-74-2
• 化学式: C₁₃H₁₅NO₂
• 分子量: 217.268
• InChiKey: MSJQCVXTUDQDRW-UHFFFAOYSA-N

物化性质

• 熔点：
  117.5-118.5 °C
• 沸点：
  448.1±34.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one 在 氢溴酸 作用下， 反应 2.0h， 生成 2-氨基-6,7,8,9-四氢-5H-苯并环庚烯-5-酮
  参考文献：
  名称：

  Selective .kappa.-Opioid Agonists: Synthesis and Structure-Activity Relationships of Piperidines Incorporating an Oxo-Containing Acyl Group

  摘要：

  This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2-(aminomethyl)piperidine derivatives, using K-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their kappa-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]-1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED(50)s of 0.47 and 0.73 mu mol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective K-agonists, has a reduced propensity to cause a number of K-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED(50) Of 26.5 mu mol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.

  DOI：

  10.1021/jm00047a006
• 作为产物：
  描述：

  4-(3-硝基苯基磺酰基)吗啉 在 palladium on activated charcoal 、 氢气 作用下， 以 溶剂黄146 为溶剂， 反应 9.0h， 生成 2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one
  参考文献：
  名称：

  INHIBITORS OF HEPATITIS C VIRUS REPLICATION

  摘要：

  本发明涉及一种具有式（I）的化合物，该化合物可用作丙型肝炎病毒（HCV）NS5A抑制剂，以及该类化合物的合成，以及利用该类化合物抑制HCV NS5A活性，用于治疗或预防HCV感染，以及在基于细胞的系统中抑制HCV病毒复制和/或病毒产生。

  公开号：

  US20190127365A1

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：MERCK SHARP & DOHME

  公开号：WO2010111483A1

  公开（公告）日：2010-09-30

  The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

  本发明涉及一种公式（I）的化合物，该化合物可用作丙型肝炎病毒（HCV）NS5A抑制剂，以及该类化合物的合成，以及利用该类化合物抑制HCV NS5A活性，用于治疗或预防HCV感染，以及在基于细胞的系统中抑制HCV病毒复制和/或病毒产生。
• Pyrazolecarboxylic acid tricyclic derivatives, preparation and pharmaceutical compositions containing same
  申请人：Barth Francis

  公开号：US06906080B1

  公开（公告）日：2005-06-14

  The subject of the invention is tricyclic derivatives of pyrazolecarboxylic acid of formula: in which R 1 represents a C 3 -C 15 carboxyl radical or an NR 2 R 3 group. The invention also relates to the method for preparing the compounds of formula (I), pharmaceutical compositions containing them. The compounds of formula (I) are active on cannabinoid CB 1 receptors.

  本发明涉及式中的吡唑羧酸三环衍生物：其中R1代表C3-C15羧基基团或NR2R3基团。本发明还涉及制备式(I)化合物的方法，含有这些化合物的药物组合物。式(I)化合物对大麻素CB1受体具有活性。
• Synthesis and biological evaluation of substituted benzo[h]cinnolinones and 3H-benzo[6,7]cyclohepta[1,2-c]pyridazinones: higher homologs of the antihypertensive and antithrombotic 5H-indeno[1,2-c]pyridazinones
  作者：Giorgio Cignarella、Daniela Barlocco、Gerard A. Pinna、Mario Loriga、Maria M. Curzu、Odoardo Tofanetti、Mauro Germini、Pietro Cazzulani、Ennio Cavalletti

  DOI：10.1021/jm00130a009

  日期：1989.10

  that of acetylsalicylic acid, most of the benzo[h]cinnolinones exhibited significant antihypertensive, inotropic, and antithrombotic properties. In this respect, the 8-amino (3b) and 8-acetylamino (3c) together with the 4,4a-dehydro analogue of 3c (11) were found to possess the most potent and long-lasting antihypertensive activity. In particular, the dextro isomer of 3c was more active than the racemic

  几个取代的苯并[h]肉桂酮3和3H-苯并[6,7]环庚[1,2-c]哒嗪酮4被设计为5H-茚并[1,2-c]哒嗪酮2的较不刚性的同类物。合成并测试为抗高血压药，正性肌力药，抗血栓药，抗炎药和抗溃疡药。尽管七元环衍生物仅显示出与乙酰水杨酸相当的抗血栓形成特性，但大多数苯并[h]肉桂醇酮显示出显着的抗高血压，正性肌力和抗血栓形成特性。在这方面，发现8-氨基（3b）和8-乙酰氨基（3c）以及3c（11）的4,4a-脱氢类似物具有最有效和最持久的降压活性。特别地，3c的右旋异构体比消旋形式更具活性，心动过速效应更低。
• Melanin concentrating hormone antagonist
  申请人：Kato Kaneyoshi

  公开号：US20070173498A1

  公开（公告）日：2007-07-26

  A melanin-concentrating hormone antagonist which comprises a compound of the formula: wherein Ar 1 is a cyclic group which may have substituents; X is a spacer having a main chain of 1 to 6 atoms; Y is a bond or a spacer having a main chain of 1 to 6 atoms; Ar is a monocyclic aromatic ring which may be condensed with a 4 to 8 membered non-aromatic ring, and may have further substituents; R 1 and R 2 are independently hydrogen atom or a hydrocarbon group which may have substituents; R 1 and R 2 , together with the adjacent nitrogen atom, may form a nitrogen-containing hetero ring which may have substituents; R 2 may form a spiro ring together with Ar; or R 2 , together with the adjacent nitrogen atom and Y, may form a nitrogen-containing hetero ring which may have substituents; or a salt thereof; which is useful as an agent for preventing or treating obesity, etc.

  一种黑色素浓集激素拮抗剂，包括一个化合物，其化学式为：其中Ar1是一个环状基团，可能具有取代基；X是一个具有1到6个原子主链的间隔物；Y是一条键或具有1到6个原子主链的间隔物；Ar是一个单环芳香环，可以与一个4到8个成员的非芳香环融合，并且可能有进一步的取代基；R1和R2分别是氢原子或一个可能具有取代基的碳氢基团；R1和R2连同相邻的氮原子可以形成一个含氮杂环，该杂环可能具有取代基；R2可以与Ar一起形成一个螺环；或者R2连同相邻的氮原子和Y可以形成一个含氮杂环，该杂环可能具有取代基；或其盐；用作预防或治疗肥胖等的药剂。
• Inhibitors of hepatitis C virus replication
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11053243B2

  公开（公告）日：2021-07-06

  The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

  本发明涉及可用作丙型肝炎病毒（HCV）NS5A 抑制剂的式 (I) 化合物、此类化合物的合成以及此类化合物用于抑制 HCV NS5A 活性、治疗或预防 HCV 感染和抑制基于细胞的系统中 HCV 病毒复制和/或病毒产生的用途。